However, despite the promising clinical advances with CDK4/6 inhibitors, 15% of the ER+/HER2− breast cancer patients show de novo or early CDK4/6 inhibitors resistance and 50% develop clinical resistance with progression within 25 months [6]. The gene discussed is ESR1; the disease is breast carcinoma.